155 related articles for article (PubMed ID: 30630678)
1. The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China.
Lan B; Ma F; Han M; Chen S; Wang W; Li Q; Fan Y; Luo Y; Cai R; Wang J; Yuan P; Zhang P; Li Q; Xu B
Clin Breast Cancer; 2019 Apr; 19(2):e370-e375. PubMed ID: 30630678
[TBL] [Abstract][Full Text] [Related]
2. The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
Lan B; Ma F; Zhai X; Li Q; Chen S; Wang J; Fan Y; Luo Y; Cai R; Yuan P; Zhang P; Li Q; Xu B
Int J Cancer; 2018 Jul; 143(1):184-189. PubMed ID: 29396856
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.
Sutiman N; Lim JSL; Muerdter TE; Singh O; Cheung YB; Ng RCH; Yap YS; Wong NS; Ang PCS; Dent R; Schroth W; Schwab M; Khor CC; Chowbay B
Clin Pharmacokinet; 2016 Oct; 55(10):1239-1250. PubMed ID: 27098059
[TBL] [Abstract][Full Text] [Related]
4. Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China.
Lan B; Ma F; Chen S; Wang W; Li Q; Fan Y; Luo Y; Cai R; Wang J; Yuan P; Zhang P; Li Q; Xu B
Int J Cancer; 2018 Nov; 143(10):2499-2504. PubMed ID: 29978573
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Punglia RS; Burstein HJ; Winer EP; Weeks JC
J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
[TBL] [Abstract][Full Text] [Related]
6. A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivatives.
Greer AK; Dates CR; Starlard-Davenport A; Edavana VK; Bratton SM; Dhakal IB; Finel M; Kadlubar SA; Radominska-Pandya A
Drug Metab Dispos; 2014 Sep; 42(9):1392-400. PubMed ID: 24917585
[TBL] [Abstract][Full Text] [Related]
7. A Simulation Study to Compare the Treatment Effect of Tamoxifen by CYP2D6 Genotypes and Third-Generation Aromatase Inhibitors.
Park GC; Jung JA; Bae KS; Lim HS
J Clin Pharmacol; 2017 Sep; 57(9):1088-1096. PubMed ID: 28369967
[TBL] [Abstract][Full Text] [Related]
8. MnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen.
Tengström M; Mannermaa A; Kosma VM; Soini Y; Hirvonen A; Kataja V
Acta Oncol; 2014 Jun; 53(6):769-75. PubMed ID: 24716840
[TBL] [Abstract][Full Text] [Related]
9. Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors.
Ahern TP; Christensen M; Cronin-Fenton DP; Lunetta KL; Søiland H; Gjerde J; Garne JP; Rosenberg CL; Silliman RA; Sørensen HT; Lash TL; Hamilton-Dutoit S
Cancer Epidemiol Biomarkers Prev; 2011 Sep; 20(9):1937-43. PubMed ID: 21750172
[TBL] [Abstract][Full Text] [Related]
10. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
[TBL] [Abstract][Full Text] [Related]
11. Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants.
Sun D; Chen G; Dellinger RW; Duncan K; Fang JL; Lazarus P
Breast Cancer Res; 2006; 8(4):R50. PubMed ID: 16884532
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Rae JM; Drury S; Hayes DF; Stearns V; Thibert JN; Haynes BP; Salter J; Sestak I; Cuzick J; Dowsett M;
J Natl Cancer Inst; 2012 Mar; 104(6):452-60. PubMed ID: 22395643
[TBL] [Abstract][Full Text] [Related]
14. SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?
Tengström M; Mannermaa A; Kosma VM; Hirvonen A; Kataja V
BMC Cancer; 2012 Jun; 12():257. PubMed ID: 22708928
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of a single-nucleotide polymorphism near the CTSO gene in hormone receptor-positive breast cancer patients.
Hato Y; Kondo N; Yoshimoto N; Endo Y; Asano T; Dong Y; Nishimoto M; Takahashi S; Fujii Y; Nakanishi R; Toyama T
Int J Clin Oncol; 2016 Jun; 21(3):539-47. PubMed ID: 26482374
[TBL] [Abstract][Full Text] [Related]
16. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
17. Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes.
Li X; Li Z; Li L; Liu T; Qian C; Ren Y; Li Z; Chen K; Ji D; Zhang M; Wang J
Cancer Res Treat; 2024 Jan; 56(1):134-142. PubMed ID: 37591782
[TBL] [Abstract][Full Text] [Related]
18. Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics.
Edavana VK; Dhakal IB; Williams S; Penney R; Boysen G; Yao-Borengasser A; Kadlubar S
Drug Metab Dispos; 2013 Apr; 41(4):870-7. PubMed ID: 23371966
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
Li L; Chang B; Jiang X; Fan X; Li Y; Li T; Wu S; Zhang J; Kariminia S; Li Q
BMC Cancer; 2018 Oct; 18(1):977. PubMed ID: 30314452
[TBL] [Abstract][Full Text] [Related]
20. Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer.
Parmar S; Stingl JC; Huber-Wechselberger A; Kainz A; Renner W; Langsenlehner U; Krippl P; Brockmöller J; Haschke-Becher E
Breast Cancer Res; 2011 Jun; 13(3):R57. PubMed ID: 21658222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
